News and Views on the SSRI Group of Drugs


  • STOP the Lies: Join the Cause: Click pic below

  • Enter your email address to subscribe to this blog and receive notifications of new posts by email.

    Join 7 other followers

  • Monthly Archive showing # of posts

  • Advertisements

Posts Tagged ‘suicide’

2011 SSRI Related Deaths

Posted by shutah on February 20, 2011

It’s Sunday, 20 February 2011

51 days into the year

43 incidents listed already


SSRI Related Deaths 2011


Does anyone care?









Posted in GlaxoSmithKline, GSK, MHRA, SSRIs | Tagged: , , , , , , , , , , , , | Leave a Comment »

When secret settlements are taken to their illogical extreme

Posted by shutah on January 26, 2011

from The Moral Compass of the American Lawyer
by Richard Zitrin & Carol M. Langford

This story is not about Prozac, which from the weight of evidence appears to be a relatively safe drug. Rather, this is a tale of what happens when secret settlements are taken to their illogical extreme — in this case, a “sham” trial in which the plaintiffs and their lawyers were paid to pull their punches so the defendant could get a favorable verdict.

It started in September 1989, when Joseph Wesbecker armed himself with an AK-47, walked into the Louisville printing plant where he had worked, and started shooting. He killed eight people, wounded twelve more, and finished matters by blowing his own brains out. One month before, Wesbecker had begun taking Prozac. The lawyers for the shooting victims soon focused on the drug as the cause for Wesbecker’s extraordinary violence, and they targeted Eli Lilly, Prozac’s manufacturer, as the “deep pocket.”

The Fentress case, named for one of Wesbecker’s victims, was the first of 160 cases pending against Prozac to go to trial in the autumn of 1994. By then, Prozac had become the aspirin of anti-depressants — the wonder drug everyone was talking about and millions were using. Prozac represented almost one-third of all Lilly sales in 1994 — $1.7 billion. A great deal was at stake: If Lilly lost, other plaintiffs waiting in the wings would gain strength and resolve. But a verdict for the drug company might make those other plaintiffs reconsider.

Throughout the case, plaintiffs’ attorneys pushed Judge John Potter to allow evidence about another Lilly product, the anti-inflammatory drug Oraflex, which had been taken off the market in 1982 as too dangerous. In 1985, Lilly had pled guilty to 25 criminal counts of failing to report adverse reactions to Oraflex, including four deaths, to the Food & Drug Administration. Central to the plaintiffs’s claims was that Lilly had done the same thing with Prozac. Potter refused to allow the evidence, saying it was marginally relevant at best, and would prejudice the jury more than it would prove anything.

But when Lilly executives testified that the company had an excellent reputation for reporting problem incidents — what they euphemistically called “adverse events” — plaintiffs’ counsel immediately renewed their request to bring in the Oraflex evidence. Potter agreed, noting that “Lilly has injected the issue into the trial.” Potter’s ruling set off a flurry of activity around his courtroom. The lawyers jointly asked for a recess, and then asked to adjourn for a day.

By mid-afternoon, a strong scent of settlement was in the air. But when Judge Potter reconvened the case the following afternoon, he was surprised by what he heard. Chief plaintiffs’ counsel Paul Smith announced that the plaintiffs would rest without presenting the Oraflex evidence unless the trial went to its second phase, which would address the amount of the financial award. That stage would occur only if the jury decided in the first phase that Lilly was liable. If the jury found Lilly not liable, the case would be over, and the Oraflex evidence would never be heard.

The plaintiffs’ high-risk strategy puzzled Judge Potter; they could lose their whole case without presenting their best evidence. Potter asked the lawyers whether they had reached a settlement. He was told unequivocally that they had not. While the jury was deliberating, a juror came forward and told Judge Potter that she had overheard settlement negotiations going on in the hallway. She repeated this in chambers with the lawyers present and was then excused. Potter turned to the lawyers and said, “Does anybody have anything they want to say?” A moment later, he asked again, “Does anybody have the slightest clue?” “No,” said Smith. “I can’t imagine,” said one of the defense lawyers.

In other chambers meetings, lawyers from both sides emphasized their plans for Phase Two of the trial — the money, or “damages” phase — and the possibility of settlement discussions if the plaintiffs won Phase One. All this would be unnecessary, of course, if the case actually had been settled already. On December 12, only three court days after Potter’s ruling allowing the Oraflex evidence, the jury returned a verdict for Lilly.

In January 1995, Judge Potter formally entered his order in Fentress v. Eli Lilly, dismissing the case after verdict by jury. As soon as the verdict was in, Lilly and its lawyers trumpeted their victory across the country. “We were able, finally,” said one of Lilly’s lead attorneys, “to get people head to head in a courtroom and say ‘Put up or shut up.’ … [T]his is a complete vindication of the medicine.”

Had John Potter not been the judge, the Fentress case might have ended there. He asked himself why any lawyer would fight so hard over the key Oraflex evidence and then not present it in the most important part of the case.

Despite what the lawyers had told him, Potter suspected that some kind of deal had been made. But he decided to be patient. He waited to see whether the plaintiffs filed a notice of their intent to appeal, a routine matter after losing a case. When they didn’t, Potter called in the lawyers from both sides. They continued to deny that a settlement had been reached. Although Potter was more suspicious than ever, he had no power to do anything, except as to his own order of dismissal. So in April 1995, stating “it is more likely than not that the case was settled,” Potter filed an unusual document: his own motion to change his post-trial order from a dismissal after verdict to “dismissed as settled.” He set a hearing for May.

Quickly, the lawyers on both sides joined forces to file an objection with Kentucky’s appeals court to prevent Judge Potter’s hearing anything about what they considered a closed case. Paul Smith stated flatly that “there was no secret settlement…. This was a hard fought case.” Potter, meanwhile, now needed a lawyer himself. After Potter’s changed order had become public, Richard Hay, then President of the Kentucky Academy of Trial Attorneys, told reporters that if money had been traded for evidence, the trial was “a sham,” like “taking a dive in a boxing match.”

Potter read Hay’s comments, called him, and asked how outraged Hay was about the case. “Enough to represent you,” Hay replied. Together, Hay and Potter filed a brief that emphasized a “public silence [that] has been bought and paid for,” robbing millions who “want the truth.”

In June 1995, the appeals court ruled against Potter, saying he no longer had jurisdiction over the case. Potter appealed to the Kentucky Supreme Court. Before the fall Supreme Court hearing, lawyers for both sides finally acknowledged that they had indeed settled all money issues and had agreed to go through only the first phase of the trial no matter what the result. Still, they refused to disclose specifics.

Meanwhile, in Indianapolis, Lilly’s hometown, Paul Smith suddenly withdrew as lead counsel in a series of consolidated Prozac cases in federal court. He wouldn’t say whether he had settled his Indianapolis cases as part of the Fentress settlement, and the judge refused to ask. In their appeal to the Supreme Court, Potter and Hay de-emphasized the importance of public disclosure, and focused instead on the lawyers’ failure to be candid with the judge.

On May 23, 1996, the Kentucky Supreme Court decided the case of Hon. John W. Potter v. Eli Lilly unanimously in Judge Potter’s favor, citing the lawyers’ “serious lack of candor” and evidence of bad faith, abuse of process, even fraud. Although the court said that “the only result” of exposing the secret Fentress agreement “is that the truth will be revealed,” the decision was less a victory for open settlements, and more a demand that the judge be included in the secret.

Judge Potter, though, still saw the larger issue. Armed with Supreme Court authority to conduct an investigation and hold a hearing, Potter asked Deputy State Attorney General Ann Sheadel to investigate, giving her the power to subpoena documents and question witnesses under oath. Sheadel’s March 1997 report uncovered new twists to the story. A complex agreement did exist between Lilly and the plaintiffs, one so secret that it was never fully reduced to writing. All Sheadel could find was a written summary of the verbal agreement. No lawyer would admit preparing it, and no plaintiff was allowed to have it.

In exchange for the plaintiffs agreeing not to present the evidence of Lilly’s criminal conduct with Oraflex, Lilly had agreed to pay all plaintiffs, win or lose. Part of the agreement was that all of chief plaintiffs’ counsel Smith’s Prozac cases, including those in Indianapolis, were settled, and half his overall expenses paid by Lilly.

Judge Potter set a hearing to take sworn testimony on March 27, 1997. The hearing never happened.

On March 24, in a surprise move, attorneys for Lilly and the plaintiffs presented Judge Potter with a new stipulation and order in Fentress showing that the case was dismissed “as settled,” exactly what Potter had insisted on two years before. The judge signed the order. Three days later, Lilly’s attorney went before the appeals court to argue that any further proceedings were now moot. He also claimed that Potter had violated judicial ethics and was on a “vendetta” against Lilly. Potter recused himself, saying “the spotlight should be on what … is under the log, not the person trying to roll it over.”

The judge had succeeded in uncovering the collusive settlement. But of the approximately 160 active Prozac cases in December 1994, less than half remained.

Inexplicably, Fentress had received almost no attention in the national media, and the Kentucky court of appeal closed any further hearings to the public. Plaintiffs’ attorney Paul Smith was still practicing law in Dallas.

And the only thing that anyone ever learned about the amount of the settlement was the comment of a Louisville lawyer who represented one of the Fentress plaintiffs in a divorce. The amount, he said, was “tremendous.”

Adopted from pages 193-201 of The Moral Compass of the American Lawyer: Truth, Justice, Power, and Greed, © 1999, Richard Zitrin & Carol M. Langford All rights reserved.
This critically acclaimed book, about how the legal system allows lawyers to define “ethics” as what they can get away with rather than how they should behave, is written by two noted legal ethics professors who write frequently about ethics and morality in the legal profession.


Posted in SSRIs | Tagged: , , , , , | Leave a Comment »

Efficacy of antidepressants in adults

Posted by shutah on January 16, 2011

Paper written by Joanna Moncrieff, Irving Kirsch and published in the British Medical Journal (BMJ) 16/07/2005

Summary points

  • Recent meta-analyses show selective serotonin reuptake inhibitors have no clinically meaningful advantage over placebo.
  • Claims that antidepressants are more effective in more severe conditions have little evidence to support them.
  • Methodological artefacts may account for the small degree of superiority shown over placebo.  Antidepressants have not been convincingly shown to affect the long term outcome of depression or suicide rates.
  • Given doubt about their benefits and concern about their risks, current recommendations for prescribing antidepressants should be reconsidered.

Effect of antidepressants

Longitudinal follow-up studies show very poor outcomes for people treated for depression both in hospital and in the community, and the overall prevalence of depression is rising despite increased useof antidepressants.

Two studies that prospectively assessed outcome in depressed patients treated naturalistically by general practitioners and psychiatrists found that people prescribed antidepressants had a slightly worse outcome than those not prescribed them, even after baseline severity had been taken into account.

No comparable studies could be found that showed a better outcome in people prescribed antidepressants.  Some authors have suggested a causal association between increased antidepressant prescribing since 1990 and reduction of overall suicide rates observed insome countries.

However, others have pointed out that falls in overall suicide rates started long before this period and suicide rates have increased in some age groups and some countries despite increased antidepressant prescribing.

Meta-analyses of data from controlled trials have not found reduced rates of suicide or suicidal behaviour in drug arms compared with placebo arms.


The NICE review data suggest that selective serotonin reuptake inhibitors do not have a clinically meaningful advantage over placebo, which is consistent with other recent meta-analyses.

In addition, methodological artefacts may account for the small effect seen. Evidence that antidepressants are more effective in more severe conditions is not strong, and data on long term outcome of depression and suicide do not provide convincing evidence of benefit.

In children, the balance of benefits to risks is now recognised as unfavourable. We suggest this may also be the case for adults, given the continuing uncertainty about the possible risk of increased suicidality as well as other known adverse effects.

This conclusion implies the need for a thorough re-evaluation of current approaches to depression and further development of alternatives to drug treatment. Since antidepressants have become society’s main response to distress, expectations raised by decades of their use will also need to be addressed.

We thank other members of the Critical Psychiatry Network who contributed to the response to the NICE depression review and especially Duncan Double, who coordinated the response. Contributors and sources: Both authors have conducted separate meta-analyses of antidepressant trials and reviews of antidepressant literature. JM has recently obtained an MD in antidepressant research methodology.  The article draws on these sources,  as well as the data contained in the NICE review. JM and IK contributed to the response to the NICE review. JMhad the idea to write the paper. JM and IK drafted and revised the current manuscript. JM will act as guarantor.
Competing interests: IK has received consulting fees fromSquibb and Pfizer. JM is co-chair of the Critical Psychiatry Network

Posted in SSRIs | Tagged: , , , , , , , , , | Leave a Comment »

Successful SSRI Criminal Cases

Posted by shutah on January 14, 2011

Here is a list Criminal Cases with successful outcomes.  Each Defendant was shown to be under the influence of an SSRI at the time of the crime [courtesy of SSRI Stories].

Click the link to open the spreadsheet where you can read about each documented case (to date)!  Sadly I have no doubt that this list will expand as time passes, unless and until the ‘establishment’ steps up to the plate and deals with this issue once and for all.

Posted in Depression, Paroxetine, Seroxat, Seroxat Legal, SSRIs | Tagged: , , , , | Leave a Comment »

Antidepressants Exposed [2006]

Posted by shutah on January 14, 2011

This really is a must watch!!!

As my colleague wrote “What a guy!”

David Healy is a psychiatrist and is currently a professor in Psychological Medicine at Cardiff University School of Medicine, Wales.   He is also the director of North Wales School of Psychological Medicine.

Posted in SSRIs | Tagged: , , , , , , , , , | Leave a Comment »